Zhejiang pharmaceutical holding company with stakes in drug manufacturing and healthcare-related businesses.
Zhejiang pharmaceutical holding company with stakes in drug manufacturing and healthcare-related businesses.
Moat: none. Diversified holding structure with no single dominant franchise.
Headquarters: Zhejiang, China · Employees: 1,348
Size Wanbangde Pharmaceutical (002082.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $823M, the 2531st largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥9.06 on 18 Nov 2026.
Performance Over six months the shares fell 52.1%, against -7.9% for the median peer and -20.0% for the China market (cap-weighted) — lowest of 19 in its peer set.
Growth Revenue fell 38.4% over the last twelve months (peer median +7.7%); the operating margin is -10.2% (peer median 10.0%).
Valuation It trades at 7.0× enterprise value to sales against a peer median of 2.9× (4th most expensive of 17).
Price implies For today's price to make sense, revenue must grow about 28% a year for seven years (Req g). Recent delivered growth is -39%, so the hurdle is +67 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 6.6 points below its cost of capital (6.9% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥854M | CN¥1.11B | CN¥1.44B | CN¥1.53B | CN¥1.77B |
| Revenue growth | — | -22% | -6% | -13% | — |
| Gross profit | CN¥445M | CN¥317M | CN¥543M | CN¥568M | CN¥862M |
| EBITDA | n/a | -CN¥23.1M | CN¥184M | CN¥169M | CN¥341M |
| Net income | -CN¥146M | -CN¥167M | CN¥55.4M | CN¥49.2M | CN¥93.3M |
| Free cash flow | CN¥707M | CN¥303M | CN¥32.3M | -CN¥199M | -CN¥406M |
| Capital expenditure | -CN¥13.5M | CN¥302M | CN¥88.4M | CN¥129M | CN¥167M |
| Total debt | CN¥1.03B | CN¥1.17B | CN¥1.06B | CN¥1.01B | CN¥912M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 002082.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -20.5% | -7.0% | 2nd lowest of 20 |
| 6-month return | -52.1% | -7.9% | lowest of 19 |
| Distance from 52-week high | -75.0% | -34.1% | lowest of 20 |
| Revenue growth (TTM) | -38.4% | +7.7% | lowest of 18 |
| Operating margin | -10.2% | 10.0% | 6th lowest of 18 |
| EV / Sales | 7.0× | 2.9× | 4th most expensive of 17 |
| Growth the price implies (Req g, 7 yrs) | 27.7% | 4.6% | most demanding of 8 |
| Growth delivered (Del g) | -39.5% | +20.3% | lowest of 8 |
| Hurdle (Req g minus delivered) | +67.2 pp | -14.8 pp | most demanding of 8 |
| ROIC minus cost of capital | -6.6 pp | -0.7 pp | 5th lowest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Wanbangde Pharmaceutical 002082.SZ | China | $823M | -52% | -38% | -10% | 7.0× | 27.7% | -39.5% |
| Zhejiang Ausun Pharmaceutical 603229.SS | China | $824M | -34% | +1% | 0% | 6.5× | n/a | n/a |
| Dezhan Healthcare 000813.SZ | China | $825M | -33% | -10% | -121% | 13.8× | n/a | n/a |
| Hunan Er-Kang Pharmaceutical 300267.SZ | China | $829M | -40% | -14% | -29% | 4.7× | n/a | n/a |
| Hygeia Healthcare 6078.HK | Hong Kong | $811M | -3% | +2% | 14% | 1.8× | 4.6% | +22.5% |
| Collegium Pharmaceutical COLL | United States | $806M | -24% | +8% | 15% | 2.3× | -2.6% | +20.3% |
| Suven Life Sciences SUVEN.NS | India | $803M | -1% | +55% | -4,452% | 789.4× | n/a | n/a |
| Bide Pharmatech 688073.SS | China | $801M | +10% | +10% | 19% | 3.1× | 13.9% | +27.7% |
| Rigel Pharmaceuticals RIGL | United States | $801M | +48% | +2% | 26% | 2.5× | 1.5% | +22.1% |
| Beijing Sun-Novo Pharmaceutical Research 688621.SS | China | $849M | -8% | -1% | -2% | 5.8× | n/a | n/a |
| Sanofi India SANOFI.NS | India | $797M | 0% | -6% | 26% | 4.1× | 16.3% | -8.7% |
| Oric Pharmaceuticals ORIC | United States | $795M | -9% | n/a | n/a | n/a | n/a | n/a |
| Jiangsu Yahong Meditech 688176.SS | China | $854M | -20% | +15% | -172% | 15.3× | n/a | n/a |
| DongKook Pharmaceutical 086450.KS | South Korea | $855M | +9% | +13% | 10% | 1.2× | -4.2% | +10.6% |
| Knight Therapeutics GUD.TO | Canada | $792M | +41% | +36% | 6% | 1.8× | 6.6% | +17.7% |
| Ironwood Pharmaceuticals IRWD | United States | $791M | +22% | +18% | 63% | 2.6× | n/a | n/a |
| Bambusa Therapeutics BBTX | United States | $791M | n/a | n/a | n/a | n/a | n/a | n/a |
| Daewoong Pharm 069620.KS | South Korea | $856M | -33% | +9% | 12% | 1.2× | n/a | n/a |
| Corvus Pharmaceuticals CRVS | United States | $860M | -16% | n/a | n/a | n/a | n/a | n/a |
| Kaken Pharmaceutical 4521.T | Japan | $860M | -8% | +5% | 10% | 0.9× | n/a | n/a |
| City Therapeutics CTY | United States | $861M | n/a | +388% | -442% | n/a | n/a | n/a |